Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · lyophilized powder, vial

Epic Peptides Lab · USA

Document number: PL-SDS-146
Revision: 1.0 · 2026-10-03

Semaglutide

lyophilized powder, vial

WARNING

1Identification

Product Identifier

Semaglutide

Document Number

PL-SDS-146

Catalogue Items Covered

Id
1803
Name
Semaglutide 30mg
Sku
PL-SEMA-30MG-VIAL
Id
1798
Name
Semaglutide 20mg
Sku
PL-SEMA-20MG-VIAL
Id
1793
Name
Semaglutide 15mg
Sku
PL-SEMA-15MG-VIAL
Id
1788
Name
Semaglutide 10mg
Sku
PL-SEMA-10MG-VIAL
Id
1783
Name
Semaglutide 5mg
Sku
PL-SEMA-5MG-VIAL

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification

Carcinogenicity — Category 2 — H351
Reproductive toxicity — Category 2 — H361

Label Elements

Pictograms: GHS08
Signal: Warning
Hazard statements: H351 Suspected of causing cancer.

H361 Suspected of damaging fertility or the unborn child.
Precautionary statements: P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing and eye protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Signal Word

Warning

Other Hazards

No data available.

3Composition / information on ingredients

Description

Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap.

Composition

Name
Semaglutide
Full
NN9535; GLP-1 receptor agonist
Cas
910463-68-2
Formula
C187H291N45O59
Conc
≥ 95% (dry basis, as supplied)
Qty
5 mg, 10 mg, 15 mg, 20 mg, 30 mg per vial
Hazards
- Carcinogenicity — Category 2 — H351
- Reproductive toxicity — Category 2 — H361

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General: If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; finely divided powder may form dust clouds. Not flammable in the quantities supplied.

6Accidental release measures

Spill And Clean Up Procedures: Avoid dust formation. Dampen spilled powder with water, wipe up with absorbent material, place in a sealed container for disposal and clean the area with water and detergent.

7Handling and storage

Safe Handling: Open vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling.
Safe Storage: Store the sealed vial at the temperature stated in Section 9 (typically −20 °C for peptides, 2–8 °C for proteins), desiccated and protected from light. Allow the vial to reach room temperature before opening to avoid condensation. Reconstituted solutions: 2–8 °C, protected from light; use within the period established by your laboratory.
Storage Temperature: −20 °C (sealed vial), desiccated and protected from light; 2–8 °C acceptable for short periods
Incompatible Materials: Strong oxidizing agents (Iris Biotech); strong acids/alkalis, strong oxidising/reducing agents (ChemicalBook); strong oxidizing agents, strong acids, strong bases (Selleck); Cayman: no further relevant information

8Exposure controls / personal protection

Occupational Exposure Limits: No data available.
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

White to off-white lyophilized powder

Properties

Odor: Characteristic (Cayman); others: no data
Ph: Not applicable (solid); aqueous solutions typically pH 4–7
Melting: Undetermined / no data available (all suppliers)
Boiling: Undetermined / not applicable
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: Cayman: slightly soluble (0.1-1 mg/ml) in acetonitrile:water 1:1; water solubility not determined. ChemicalBook: DMSO 3 mg/mL (0.73 mM). Selleck: water <1 mg/mL.
Logp: No data available
Decomp: No data available; peptides decompose above about 200 °C
Other: Non-flammable (Iris Biotech). CAS 910463-68-2; C187H291N45O59, MW 4113.6; Aib8, Arg34, Lys26-(C18 diacid-gamma-Glu-2xOEG) GLP-1 analogue; EC 691-729-9 (Bachem). Sodium salt CAS 2924330-56-1

10Stability and reactivity

Stability And Reactivity

Reactivity: Chemically stable under recommended storage conditions (Bachem, Iris Biotech); no dangerous reactions known (Cayman)
Incompatible: Strong oxidizing agents (Iris Biotech); strong acids/alkalis, strong oxidising/reducing agents (ChemicalBook); strong oxidizing agents, strong acids, strong bases (Selleck); Cayman: no further relevant information
Decomposition: Thermal decomposition can release irritating gases and vapours (Bachem); CO2, CO, NOx (Iris Biotech); under fire conditions may decompose and emit toxic fumes (ChemicalBook)
Conditions To Avoid: Moisture and heat (Iris Biotech); light; repeated freeze-thaw; store -20 °C desiccated

Conditions To Avoid

Moisture and heat (Iris Biotech); light; repeated freeze-thaw; store -20 °C desiccated

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
No LD50 data available in any SDS. Cayman/Selleck classify Acute Tox. 4 oral (H302) without quoted values; Bachem: classification criteria not met

Acute toxicity, dermal
No data available; Cayman/Selleck classify Acute Tox. 4 dermal (H312); Bachem: criteria not met

Acute toxicity, inhalation
No data available; Cayman/Selleck classify Acute Tox. 4 inhalation (H332); Bachem: criteria not met

Skin corrosion/irritation
Cayman: irritant to skin and mucous membranes (Skin Irrit. 2). Bachem: criteria not met

Serious eye damage/irritation
Cayman: irritating effect (Eye Irrit. 2A). Bachem: criteria not met

Respiratory or skin sensitisation
No sensitizing effects known (Cayman); criteria not met (Bachem)

Germ cell mutagenicity
No data available / criteria not met (Bachem)

Carcinogenicity
Not listed by IARC, NTP or OSHA. Cayman and Selleck classify Carc. 2 (H351) - consistent with the dose- and duration-dependent thyroid C-cell tumours in rodent carcinogenicity studies that underlie the FDA boxed warning. Bachem: criteria not met

Reproductive toxicity
All suppliers classify as a reproductive toxicant: Cayman Repr. 1A (H360), Selleck H360D/H361, Bachem Repr. 2 H361d (suspected of damaging the unborn child), Iris Biotech Repr. 2 H361, ChemicalBook H361.

STOT, single exposure
Cayman/Selleck: STOT SE 3 (respiratory irritation, H335); Bachem: criteria not met

STOT, repeated exposure
Cayman/Selleck: STOT RE 2 (H373); Bachem: criteria not met

Aspiration hazard
No data available
Routes Of Exposure: Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman and Iris Biotech: water hazard class 3 (self-assessment) - extremely/highly hazardous for water; no measured aquatic toxicity, persistence or bioaccumulation data in any SDS. Bachem: not tested; does not meet PBT/vPvB criteria.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Substance is not listed (Cayman, Selleck)
Carcinogen Listings: Not listed by IARC, NTP, OSHA or EPA; not Prop 65 listed (Selleck, ChemicalBook)
Dea: Not a controlled substance
Other: FDA-approved prescription drug (Novo Nordisk: Ozempic, Wegovy, Rybelsus) with boxed warning for risk of thyroid C-cell tumours. Not listed under SARA 313 (Cayman). EU: Bachem SDS notes maternity-protection (92/85/EEC) and juvenile-work (94/33/EC) employment restrictions because of the Repr. classification; not SEVESO III (Iris Biotech). WADA remark: GLP-1 receptor agonists are not on the WADA Prohibited List (verify current list).

Carcinogen Listings

Semaglutide is self-classified Carc. 2 on rodent data (see above)

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

Selleck Chemicals

Bachem

Iris Biotech

ChemicalBook
Confidence: high
Additional Information: GLP-1 receptor agonist. Approved members of this class carry label warnings for embryo-fetal toxicity in animals (fetal growth reduction and malformations at clinically relevant exposures) and for thyroid C-cell tumours in rodents. PrymaLab classifies the substance as Reproductive toxicity Category 2 (H361) by read-across to the class.

Back to SDS list